Vikram V. Kulkarni

Vikram V. Kulkarni

Auto-generated profile, based on publicly available information

Vikram V. Kulkarni

Pulmonary Medicine, MD Anderson Cancer Center, Houston, TX, United States

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 January 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
ECEvelyn M. Covés-Datson
Evelyn M. Covés-Datson
SKSteven R. King
Steven R. King
MLMaureen Legendre
Maureen Legendre
AGAuroni Gupta
Auroni Gupta
SCSusana M. Chan
Susana M. Chan
DMDavid M. Markovitz
David M. Markovitz
Significance: There is a pressing need for new antiinfluenza therapeutic agents. We show that a molecularly engineered banana lectin (carbohydrate-binding protein) has broad-spectrum activity against all influenza strains tested, including drug-resistant and currently circulating strains; is safe upon repeated administration in mice; and, moreover, is efficacious at treating lethal influenza infection via clinically pertinent routes of administration. We demonstrate that the lectin binds to the viral hemagglutinin glycoprotein and exerts its primary antiviral effect via inhibition of an early stage of the viral life cycle, viral membrane fusion to the host endosomal membrane. Our findings indicate that this engineered lectin, which has a mechanism of action quite distinct from the presently available agents, has potential as an antiinfluenza agent.

5 July 2018 in mBio
Verified
Journal Article
Open access
CKCarson T. Kirkpatrick
Carson T. Kirkpatrick
YWYongxing Wang
Yongxing Wang
MJMiguel M. Leiva Juarez
Miguel M. Leiva Juarez
PSPooja Shivshankar
Pooja Shivshankar
JGJezreel Pantaleón García
Jezreel Pantaleón García
SEScott E. Evans
Scott E. Evans
Viral pneumonias cause profound worldwide morbidity, necessitating novel strategies to prevent and treat these potentially lethal infections. Stimulation of intrinsic lung defenses via inhalation of synergistically acting Toll-like receptor (TLR) agonists protects mice broadly against pneumonia, including otherwise-lethal viral infections, providing a potential opportunity to mitigate infectious threats. As intact lung epithelial TLR signaling is required for the inducible resistance and as these cells are the principal targets of many respiratory viruses, the capacity of lung epithelial cells to be therapeutically manipulated to function as autonomous antiviral effectors was investigated. Our work revealed that mouse and human lung epithelial cells could be stimulated to generate robust antiviral responses that both reduce viral burden and enhance survival of isolated cells and intact animals. The antiviral protection required concurrent induction of epithelial reactive oxygen species (ROS) from both mitochondrial and dual oxidase sources, although neither type I interferon enrichment nor type I interferon signaling was required for the inducible protection. Taken together, these findings establish the sufficiency of lung epithelial cells to generate therapeutically inducible antiviral responses, reveal novel antiviral roles for ROS, provide mechanistic insights into inducible resistance, and may provide an opportunity to protect patients from viral pneumonia during periods of peak vulnerability. IMPORTANCE Viruses are the most commonly identified causes of pneumonia and inflict unacceptable morbidity, despite currently available therapies. While lung epithelial cells are principal targets of respiratory viruses, they have also been recently shown to contribute importantly to therapeutically inducible antimicrobial responses. This work finds that lung cells can be stimulated to protect themselves against viral challenges, even in the absence of leukocytes, both reducing viral burden and improving survival. Further, it was found that the protection occurs via unexpected induction of reactive oxygen species (ROS) from spatially segregated sources without reliance on type I interferon signaling. Coordinated multisource ROS generation has not previously been described against viruses, nor has ROS generation been reported for epithelial cells against any pathogen. Thus, these findings extend the potential clinical applications for the strategy of inducible resistance to protect vulnerable people against viral infections and also provide new insights into the capacity of lung cells to protect against infections via novel ROS-dependent mechanisms.

18 August 2016 in Blood
Verified
Journal Article
Open access
PDF file
MLMiguel M. Leiva-Juárez
Miguel M. Leiva-Juárez
HWHayden H. Ware
Hayden H. Ware
VKVikram V. Kulkarni
Vikram V. Kulkarni
PZPatrick A. Zweidler-McKay
Patrick A. Zweidler-McKay
MTMichael J. Tuvim
Michael J. Tuvim
SEScott E. Evans
Scott E. Evans
Key Points: Survival of acute myelogenous leukemia is frequently limited by pneumonia, due to disease- and therapy-associated immune defects. Inducible epithelial resistance protects neutropenic, leukemic mice against lethal pneumonia without impacting AML cell proliferation.

22 February 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
HWHayden H. Ware
Hayden H. Ware
VKVikram V. Kulkarni
Vikram V. Kulkarni
YWYongxing Wang
Yongxing Wang
JGJezreel Pantaleón García
Jezreel Pantaleón García
MJMiguel Leiva Juarez
Miguel Leiva Juarez
SEScott E. Evans
Scott E. Evans
Pneumonia remains a global health threat, in part due to expanding categories of susceptible individuals and increasing prevalence of antibiotic resistant pathogens. However, therapeutic stimulation of the lungs’ mucosal defenses by inhaled exposure to a synergistic combination of Toll-like receptor (TLR) agonists known as Pam2-ODN promotes mouse survival of pneumonia caused by a wide array of pathogens. This inducible resistance to pneumonia relies on intact lung epithelial TLR signaling, and inducible protection against viral pathogens has recently been shown to require increased production of epithelial reactive oxygen species (ROS) from multiple epithelial ROS generators. To determine whether similar mechanisms contribute to inducible antibacterial responses, the current work investigates the role of ROS in therapeutically-stimulated protection against Pseudomonas aerugnosa challenges. Inhaled Pam2-ODN treatment one day before infection prevented hemorrhagic lung cytotoxicity and mouse death in a manner that correlated with reduction in bacterial burden. The bacterial killing effect of Pam2-ODN was recapitulated in isolated mouse and human lung epithelial cells, and the protection correlated with inducible epithelial generation of ROS. Scavenging or targeted blockade of ROS production from either dual oxidase or mitochondrial sources resulted in near complete loss of Pam2-ODN-induced bacterial killing, whereas deficiency of induced antimicrobial peptides had little effect. These findings support a central role for multisource epithelial ROS in inducible resistance against a bacterial pathogen and provide mechanistic insights into means to protect vulnerable patients against lethal infections.

1 May 1990 in Journal of Biomedical Engineering
Verified
Journal Article
Closed access
VKV. Kulkarni
V. Kulkarni
JHJ.M.S. Hutchison
J.M.S. Hutchison
IRI.K. Ritchie
I.K. Ritchie
JMJ.R. Mallard
J.R. Mallard
We used the Aberdeen impedance imaging system to drive a constant current of 1 mA on a 10 kHz sine wave into the upper arm encircled by an elastic belt of 16 equi-spaced strip electrodes. The system was used to examine a normal upper arm, an upper arm with a recent humeral fracture and an upper arm with a clinically united fracture. We approximated the human upper arm to a circular cylinder and assumed bilateral symmetry of normal human limbs. We measured transverse limb resistivity ratios and reconstructed static two-dimensional images of the spatial distribution of log(resistivity) by the equipotential back projection technique using a homogeneous muscle equivalent saline reference. Our results indicate that impedance osteography provides unique information about the changing electrical characteristics at the fracture site. This information could prove a useful adjunct to clinical and radiological tests for fracture union.

1 May 2023
Verified
Conference Paper
Closed access
MNM. Ntita
M. Ntita
MLM. K. Longmire
M. K. Longmire
Yinghong WangYinghong Wang
Yinghong Wang
JPJ. Pantaleon-Garcia
J. Pantaleon-Garcia
VKV. Kulkarni
V. Kulkarni
ESE.E. Scott
E.E. Scott